Top

Reactions Weekly

Published in:

01-01-2023 | NSCLC | Case report

Ceritinib/crizotinib

Drug resistance and no therapeutic response: 6 case reports

Published in: Reactions Weekly | Issue 1/2023

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Kwon M, et al. Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors. Cancer Medicine 11: 2944-2956, No. 15, Aug 2022. Available from: URL: http://doi.org/10.1002/cam4.4663

Title: Ceritinib/crizotinib
Drug resistance and no therapeutic response: 6 case reports
Publication date: 01-01-2023
Publisher: Springer International Publishing
Keywords: NSCLC
Tyrosine Kinase Inhibitors
NSCLC
Tyrosine Kinase Inhibitors
Ceritinib
Crizotinib
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-31544-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Ceritinib/crizotinib

Drug resistance and no therapeutic response: 6 case reports

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Levamisole

Rotavirus vaccine

Antineoplastics

Paclitaxel/sorafenib

Ibuprofen/omeprazole

Multiple drugs